Lazard Asset Management LLC boosted its stake in Encompass Health Co. (NYSE:EHC – Get Rating) by 2,453.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,298 shares of the company’s stock after purchasing an additional 2,208 shares during the quarter. Lazard Asset Management LLC’s holdings in Encompass Health were worth $128,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of EHC. Baupost Group LLC MA grew its position in Encompass Health by 318.9% in the first quarter. Baupost Group LLC MA now owns 3,000,000 shares of the company’s stock valued at $213,330,000 after acquiring an additional 2,283,900 shares during the last quarter. State Street Corp grew its position in Encompass Health by 5.0% in the first quarter. State Street Corp now owns 2,733,254 shares of the company’s stock valued at $195,118,000 after acquiring an additional 130,504 shares during the last quarter. Victory Capital Management Inc. grew its position in Encompass Health by 40.0% in the second quarter. Victory Capital Management Inc. now owns 2,146,910 shares of the company’s stock valued at $120,335,000 after acquiring an additional 613,547 shares during the last quarter. Bank of New York Mellon Corp grew its position in Encompass Health by 33.3% in the first quarter. Bank of New York Mellon Corp now owns 2,099,763 shares of the company’s stock valued at $149,314,000 after acquiring an additional 524,766 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Encompass Health by 21.0% in the first quarter. Dimensional Fund Advisors LP now owns 1,464,313 shares of the company’s stock valued at $104,127,000 after acquiring an additional 254,385 shares during the last quarter. Institutional investors and hedge funds own 93.07% of the company’s stock.
Encompass Health Stock Down 0.3 %
Shares of NYSE:EHC opened at $55.86 on Tuesday. The company has a market capitalization of $5.57 billion, a PE ratio of 20.66, a price-to-earnings-growth ratio of 2.72 and a beta of 1.06. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.21 and a quick ratio of 1.21. The business has a fifty day moving average price of $50.92 and a two-hundred day moving average price of $53.61. Encompass Health Co. has a 1 year low of $44.33 and a 1 year high of $74.61.
Encompass Health Announces Dividend
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on the company. Raymond James lifted their target price on Encompass Health from $65.00 to $72.00 and gave the company a “strong-buy” rating in a research report on Friday, October 28th. Truist Financial reduced their price target on Encompass Health from $75.00 to $65.00 and set a “buy” rating on the stock in a report on Monday, August 8th. Deutsche Bank Aktiengesellschaft cut their price objective on Encompass Health from $80.00 to $62.00 in a research note on Wednesday, August 3rd. Stephens dropped their price target on Encompass Health from $60.00 to $58.00 and set an “overweight” rating on the stock in a research note on Friday, October 28th. Finally, Barclays dropped their price target on Encompass Health from $80.00 to $63.00 and set an “overweight” rating on the stock in a research note on Thursday, August 4th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Encompass Health currently has an average rating of “Buy” and a consensus target price of $64.13.
Insider Transactions at Encompass Health
In other news, Director Greg D. Carmichael purchased 1,830 shares of the business’s stock in a transaction dated Monday, October 31st. The stock was bought at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the purchase, the director now owns 10,546 shares of the company’s stock, valued at $576,549.82. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.70% of the stock is owned by corporate insiders.
Encompass Health Company Profile
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
- Get a free copy of the StockNews.com research report on Encompass Health (EHC)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Is Ardelyx is A Buy After Slip in Early 2022
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.